Naoki Ito

Dr. Naoki Ito

Foundation for Biomedical Research and Innovation at Kobe (FBRI)
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Cell Metabolism
Verified
Journal Article
Closed access
NSNoriaki Shimizu
Noriaki Shimizu
NYNoritada Yoshikawa
Noritada Yoshikawa
NINaoki Ito
Naoki Ito
TMTakako Maruyama
Takako Maruyama
YSYuko Suzuki
Yuko Suzuki
HTHirotoshi Tanaka
Hirotoshi Tanaka

2 December 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NINaoki Ito
Naoki Ito
URUrs T. RUEGG
Urs T. RUEGG
AKAkira Kudo
Akira Kudo
YMYuko Miyagoe-Suzuki
Yuko Miyagoe-Suzuki
STShin'IChi Takeda
Shin'IChi Takeda

30 March 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HMHideya Mizuno
Hideya Mizuno
ANAkinori Nakamura
Akinori Nakamura
YAYoshitsugu Aoki
Yoshitsugu Aoki
NINaoki Ito
Naoki Ito
SKSoichiro Kishi
Soichiro Kishi
KHKazuo Hashido
Kazuo Hashido
Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder caused by mutations in the dystrophin gene, which encodes a cytoskeletal protein, dystrophin. Creatine kinase (CK) is generally used as a blood-based biomarker for muscular disease including DMD, but it is not always reliable since it is easily affected by stress to the body, such as exercise. Therefore, more reliable biomarkers of muscular dystrophy have long been desired. MicroRNAs (miRNAs) are small, ∼22 nucleotide, noncoding RNAs which play important roles in the regulation of gene expression at the post-transcriptional level. Recently, it has been reported that miRNAs exist in blood. In this study, we hypothesized that the expression levels of specific serum circulating miRNAs may be useful to monitor the pathological progression of muscular diseases, and therefore explored the possibility of these miRNAs as new biomarkers for muscular diseases. To confirm this hypothesis, we quantified the expression levels of miRNAs in serum of the dystrophin-deficient muscular dystrophy mouse model, mdx, and the canine X-linked muscular dystrophy in Japan dog model (CXMDJ), by real-time PCR. We found that the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased in both mdx and CXMDJ. Interestingly, unlike CK levels, expression levels of these miRNAs in mdx serum are little influenced by exercise using treadmill. These results suggest that serum miRNAs are useful and reliable biomarkers for muscular dystrophy.

23 February 2017 in Brain
Verified
Journal Article
Open access
PDF file
YAYoshitsugu Aoki
Yoshitsugu Aoki
RMRaquel Manzano
Raquel Manzano
YLYi Lee
Yi Lee
RDRuxandra Dafinca
Ruxandra Dafinca
MAMisako Aoki
Misako Aoki
MWMatthew Wood
Matthew Wood
A non-coding hexanucleotide repeat expansion in intron 1 of the C9orf72 gene is the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD), however, the precise molecular mechanism by which the C9orf72 hexanucleotide repeat expansion directs C9ALS/FTD pathogenesis remains unclear. Here, we report a novel disease mechanism arising due to the interaction of C9ORF72 with the RAB7L1 GTPase to regulate vesicle trafficking. Endogenous interaction between C9ORF72 and RAB7L1 was confirmed in human SH-SY5Y neuroblastoma cells. The C9orf72 hexanucleotide repeat expansion led to haploinsufficiency resulting in severely defective intracellular and extracellular vesicle trafficking and a dysfunctional trans-Golgi network phenotype in patient-derived fibroblasts and induced pluripotent stem cell-derived motor neurons. Genetic ablation of RAB7L1or C9orf72 in SH-SY5Y cells recapitulated the findings in C9ALS/FTD fibroblasts and induced pluripotent stem cell neurons. When C9ORF72 was overexpressed or antisense oligonucleotides were targeted to the C9orf72 hexanucleotide repeat expansion to upregulate normal variant 1 transcript levels, the defective vesicle trafficking and dysfunctional trans-Golgi network phenotypes were reversed, suggesting that both loss- and gain-of-function mechanisms play a role in disease pathogenesis. In conclusion, we have identified a novel mechanism for C9ALS/FTD pathogenesis highlighting the molecular regulation of intracellular and extracellular vesicle trafficking as an important pathway in C9ALS/FTD pathogenesis.

25 June 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
NINaoki Ito
Naoki Ito
SSShinobu Seki
Shinobu Seki
FUFumitaka Ueda
Fumitaka Ueda
Skin is a major safeguard tissue in humans. Because biological barrier function is deteriorated by several kinds of stresses including exposure to ultra-violet (UV) rays, the protection and treatment of skin conditions by dietary supplements are important. We therefore evaluated the effects of dietary supplementation with an algal food-derived antioxidant, astaxanthin, on UV-induced skin deterioration. Twenty-three healthy Japanese participants were recruited to a 10-week double-blind placebo-controlled study. They were assigned to the astaxanthin group supplemented with a capsule containing 4 mg of astaxanthin or the placebo group. To assess the protective role of astaxanthin for UV-induced skin deterioration, we determined the minimal erythema dose (MED) and analyzed UV-induced changes of moisture and transepidermal water loss (TEWL) at baseline and after 9 weeks of supplementation. Subjective skin conditions were assessed by the visual analog scale. The astaxanthin group showed increased MED compared with placebo. In addition, the astaxanthin group had a reduced loss of skin moisture in the irradiated area compared with placebo. Subjective skin conditions for “improvement of rough skin” and “texture” in non-irradiated areas were significantly improved by astaxanthin. Astaxanthin seems protective against UV-induced skin deterioration and helps maintain healthy skin in healthy people.

1 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NSNoriaki Shimizu
Noriaki Shimizu
TMTakako Maruyama
Takako Maruyama
NYNoritada Yoshikawa
Noritada Yoshikawa
RMRyo Matsumiya
Ryo Matsumiya
YMYanxia Ma
Yanxia Ma
HTHirotoshi Tanaka
Hirotoshi Tanaka
Skeletal muscle has a pleiotropic role in organismal energy metabolism, for example, by storing protein as an energy source, or by excreting endocrine hormones. Muscle proteolysis is tightly controlled by the hypothalamus-pituitary-adrenal signalling axis via a glucocorticoid-driven transcriptional programme. Here we unravel the physiological significance of this catabolic process using skeletal muscle-specific glucocorticoid receptor (GR) knockout (GRmKO) mice. These mice have increased muscle mass but smaller adipose tissues. Metabolically, GRmKO mice show a drastic shift of energy utilization and storage in muscle, liver and adipose tissues. We demonstrate that the resulting depletion of plasma alanine serves as a cue to increase plasma levels of fibroblast growth factor 21 (FGF21) and activates liver-fat communication, leading to the activation of lipolytic genes in adipose tissues. We propose that this skeletal muscle-liver-fat signalling axis may serve as a target for the development of therapies against various metabolic diseases, including obesity.